Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Due to the decline of COVID-19 patients on Dutch ICUs. A sample size reestimation based on blinded study data of 66 patients was furthermore favorable, indicating sufficient power to detect a difference in primary endpoint between groups.

Conditions

ARDS
Acute Respiratory Distress Syndrome
Covid19
Endothelial Dysfunction
Pulmonary Edema

Interventions

DRUG: Imatinib Mesylate intravenous solution
DRUG: Placebo

Sponsor

Dr. Jurjan Aman

Collaborators

[object Object]
[object Object]
[object Object]